Zkusit zdarma
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Cena:
$ 247.05
-0.46 (-0.19%)
Valuace
100
Růst
85
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

1:01 09-05-2026

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript...

Ascendis Pharma Reports First Quarter 2026 Financial Results

Ascendis Pharma Reports First Quarter 2026 Financial Results

7:30 07-05-2026

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than ...

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

16:01 30-04-2026

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann...

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028

16:31 21-04-2026

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today ann...

Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND

Assetmark Inc. Has $1.83 Million Stake in Ascendis Pharma A/S $ASND

3:24 21-04-2026

Assetmark Inc. raised its holdings in Ascendis Pharma A/S (NASDAQ: ASND) by 48.1% in the undefined q...

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

Ascendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United States

16:01 06-04-2026

- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric pat...

Braun Stacey Associates Inc. Buys 25,148 Shares of Ascendis Pharma A/S $ASND

Braun Stacey Associates Inc. Buys 25,148 Shares of Ascendis Pharma A/S $ASND

4:35 05-04-2026

Braun Stacey Associates Inc. grew its stake in Ascendis Pharma A/S (NASDAQ: ASND) by 26.8% in the un...

Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND

Allspring Global Investments Holdings LLC Has $40.02 Million Stock Position in Ascendis Pharma A/S $ASND

3:09 03-04-2026

Allspring Global Investments Holdings LLC lessened its holdings in shares of Ascendis Pharma A/S (NA...

Ascendis Pharma A/S (NASDAQ:ASND) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

Ascendis Pharma A/S (NASDAQ:ASND) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

4:33 01-04-2026

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report)'s share price passed above its 50-day moving av...

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

8:30 17-03-2026

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar...

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

3:36 17-03-2026

Bamco Inc. NY bought a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) during the undefine...

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND

3:30 15-03-2026

Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in th...

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND

4:02 12-03-2026

Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 28...

Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

2:10 10-03-2026

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) has earned a consensus rating of "Moderate Buy"...

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript

14:42 04-03-2026

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript...

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges

12:05 03-03-2026

Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges...

Ascendis Pharma FY 2025 Results: More Than A Takeover Story

Ascendis Pharma FY 2025 Results: More Than A Takeover Story

7:33 12-02-2026

Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rap...

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

20:24 11-02-2026

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript...

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

16:01 11-02-2026

COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno...

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

16:01 04-02-2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno...

close

ASCENDIS PHARMA REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS

11-02-2026
COPENHAGEN, DENMARK, FEB. 11, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS PHARMA TO REPORT FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON FEBRUARY 11, 2026

04-02-2026
COPENHAGEN, DENMARK, FEB. 04, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS PHARMA PROVIDES BUSINESS AND STRATEGIC ROADMAP UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

09-01-2026
COPENHAGEN, DENMARK, JAN. 09, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY PROV...
Více zde

WEEK 52 COACH TRIAL TOPLINE RESULTS CONFIRM CONSISTENT AND DURABLE TREATMENT BENEFITS IN CHILDREN WITH ACHONDROPLASIA (ACH)

08-01-2026
– ONCE-WEEKLY TRANSCON ® CNP AND TRANSCON ® HGH COMBINATION THERAPY SHOWED DURABLE GROWTH WITHOU...
Více zde

ASCENDIS PHARMA TO PARTICIPATE IN THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

05-01-2026
COPENHAGEN, DENMARK, JAN. 05, 2026 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR TRANSCON CNP (NAVEPEGRITIDE) FOR CHILDREN WITH ACHONDROPLASIA

25-11-2025
–  PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE EXTENDED BY THREE MONTHS TO FEBRUARY 28, 2026...
Více zde

RESULTS OF PIVOTAL APPROACH TRIAL OF TRANSCON® CNP (NAVEPEGRITIDE) IN CHILDREN WITH ACHONDROPLASIA PUBLISHED IN JAMA PEDIATRICS

17-11-2025
COPENHAGEN, DENMARK, NOV. 17, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS PHARMA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

12-11-2025
–   Q3 2025 REVENUE OF €143.1 MILLION FOR YORVIPATH ® AND €50.7 MILLION FOR SKYTROFA ®...
Více zde

NEW POOLED 3-YEAR ANALYSIS CONFIRMS SUSTAINED, CLINICALLY MEANINGFUL IMPROVEMENTS IN RENAL FUNCTION FOR TRANSCON® PTH (PALOPEGTERIPARATIDE)-TREATED ADULTS WITH HYPOPARATHYROIDISM

07-11-2025
COPENHAGEN, DENMARK, NOV. 07, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS PHARMA TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON NOVEMBER 12, 2025

05-11-2025
COPENHAGEN, DENMARK, NOV. 05, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

3-YEAR RENAL DATA IN ADULTS WITH HYPOPARATHYROIDISM TREATED WITH TRANSCON® PTH (PALOPEGTERIPARATIDE) TO BE SHARED AT KIDNEY WEEK 2025

03-11-2025
COPENHAGEN, DENMARK, NOV. 03, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS SUBMITS MARKETING AUTHORISATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR TRANSCON® CNP FOR TREATMENT OF CHILDREN WITH ACHONDROPLASIA

08-10-2025
COPENHAGEN, DENMARK, OCT. 08, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS TO SHARE LATEST ENDOCRINOLOGY RARE DISEASE DATA IN 3 ORAL PRESENTATIONS AT ASBMR 2025

02-09-2025
COPENHAGEN, DENMARK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANN...
Více zde

ASCENDIS PHARMA TO PARTICIPATE IN THE 2025 WELLS FARGO HEALTHCARE CONFERENCE

28-08-2025
COPENHAGEN, DENMARK, AUG. 28, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS PHARMA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

07-08-2025
– Q2 2025 REVENUE OF €103.0 MILLION FOR YORVIPATH ® AND €50.7 MILLION FOR SKYTROFA ® – TRA...
Více zde

ASCENDIS PHARMA TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON AUGUST 7, 2025

31-07-2025
COPENHAGEN, DENMARK, JULY 31, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

FDA APPROVES SKYTROFA® (LONAPEGSOMATROPIN-TCGD) FOR THE ONCE-WEEKLY TREATMENT OF ADULTS WITH GROWTH HORMONE DEFICIENCY

28-07-2025
FIRST OF MANY PLANNED LABEL EXPANSIONS SUPPORTING VISION 2030 GOAL TO BECOME THE LEADING ENDOCRINOLO...
Více zde

NEW 3-YEAR PHASE 3 DATA CONFIRMED SUSTAINED RESPONSE TO TRANSCON® PTH (PALOPEGTERIPARATIDE) THERAPY IN ADULTS WITH HYPOPARATHYROIDISM, INCLUDING IMPROVEMENTS IN BIOCHEMISTRIES, KIDNEY FUNCTION, AND QUALITY OF LIFE

14-07-2025
COPENHAGEN, DENMARK, JULY 14, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

ASCENDIS TO SHARE ITS LATEST ENDOCRINOLOGY RARE DISEASE DATA AT ENDO 2025

07-07-2025
COPENHAGEN, DENMARK, JULY 07, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

TRANSCON® HGH BOOSTED TREATMENT BENEFITS OF TRANSCON® CNP IN CHILDREN WITH ACHONDROPLASIA AT WEEK 26 INTERIM ANALYSIS OF THE PHASE 2 COACH TRIAL

09-06-2025
- FOR THE TRANSCON CNP TREATMENT-NAÏVE COHORT, COMBINATION TREATMENT RESULTED IN MEAN ANNUALIZED GR...
Více zde

FDA ACCEPTS TRANSCON® CNP NDA FOR PRIORITY REVIEW

02-06-2025
– ONCE-WEEKLY TRANSCON CNP DEMONSTRATED SIGNIFICANTLY HIGHER ANNUALIZED GROWTH VELOCITY, THE PRIMA...
Více zde

CERRADO GOLD AND ASCENDANT RESOURCES ANNOUNCE COMPLETION OF BUSINESS COMBINATION TRANSACTION

20-05-2025
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, O...
Více zde

NEW DATA SHOWS IMPROVEMENTS IN GROWTH AND BONE MORPHOMETRY IN CHILDREN WITH ACHONDROPLASIA TREATED WITH TRANSCON® CNP (NAVEPEGRITIDE)

13-05-2025
COPENHAGEN, DENMARK, MAY 13, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOU...
Více zde

NEW 4-YEAR DATA SHOWS SUSTAINED RESPONSE TO TRANSCON® PTH (PALOPEGTERIPARATIDE) THERAPY IN ADULTS WITH HYPOPARATHYROIDISM

12-05-2025
COPENHAGEN, DENMARK, MAY 12, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOU...
Více zde

ASCENDIS TO SHARE ITS LATEST ENDOCRINOLOGY RARE DISEASE DATA AT ESPE & ESE 2025

05-05-2025
COPENHAGEN, DENMARK, MAY 05, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNOU...
Více zde

ASCENDIS PHARMA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

01-05-2025
- Q1 2025 REVENUE OF €44.7 MILLION FOR YORVIPATH ® AND €51.3 MILLION FOR SKYTROFA ® - TRANSCON...
Více zde

ASCENDIS PHARMA TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 1, 2025

24-04-2025
COPENHAGEN, DENMARK, APRIL 24, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANN...
Více zde

ASCENDANT RESOURCES NOTIFIES SHAREHOLDERS OF UPCOMING SPECIAL MEETING

14-04-2025
TORONTO, ON / ACCESS NEWSWIRE / APRIL 14, 2025 / FURTHER TO ITS PRESS RELEASE ON FEBRUARY 3, 2025, A...
Více zde

ASCENDIS SUBMITS U.S. NDA FOR TRANSCON CNP (NAVEPEGRITIDE) FOR THE TREATMENT OF CHILDREN WITH ACHONDROPLASIA

31-03-2025
—  DATA DEMONSTRATED MULTIPLE CLINICAL BENEFITS BEYOND LINEAR GROWTH —  NDA SUPPORTED BY DAT...
Více zde

ASCENDIS PHARMA TO PARTICIPATE IN THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE

24-02-2025
COPENHAGEN, DENMARK, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ASCENDIS PHARMA A/S (NASDAQ: ASND) TODAY ANNO...
Více zde

close

Dokumenty nejsou k dispozici

preloader